Clinical Validation of a Combinatorial Pharmacogenomic Approach in Major Depressive Disorder

Major Depressive Disorder Clinical Trial

— PANDORA  

Official title:

Towards Precision Medicine in Psychiatry: Clinical Validation of a Combinatorial Pharmacogenomic Approach.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04615234
• Other study ID #: RF-2016-02361697
• Status: Recruiting
• Start date: February 1, 2020
• Est. completion date: March 1, 2023

Study information

• Verified date: September 2022
• Source: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
• Contact: Antonio Vita, Prof
• Phone: + 39 0303995233
• Email: antonio.vita[@]unibs.it
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Major depressive disorder (MDD) is a common, chronic, debilitating mood disorder causing serious functional impairment and significantly decreased quality of life. Pharmacotherapy represents the first-line treatment choice; however, only about one third of patients respond to the first trial because of antidepressants ineffectiveness or side-effects. This causes suffering for patients and their families and significantly contributes to pushing up costs for healthcare services. Precision medicine in psychiatry might offer to clinicians the possibility to tailor the treatment according to the best possible evidence of effectiveness and tolerability for each subject. In this context our study aims to carry out a clinical validation of a combinatorial pharmacogenomics (PGx) test in an Italian MDD patient cohort with an advocacy license independence.

Our study is a prospective single-blind randomized controlled clinical observational trial enrolling 300 MDD patients. Patients referred to psychiatric services due to the failure and/or the onset of adverse effects of their current treatment for receiving a new antidepressant. Eligible participants with a primary diagnosis of MDD according to DSM-5 criteria and a Hamilton Depression Rating Scale (HAM-D17) with a score > 14 are randomized to TGTG group (Treated with Genetic Test Guide) or TAU group (Treated as Usual). For all subjects, buccal brush for DNA is collected. The primary outcome is the reduction in depressive symptomatology as measured by HAM-D17. The secondary outcomes involve a range of scales that assess MDD symptoms and social functioning outcomes. The assessment is performed at four timepoints: baseline and 4, 8, and 12 weeks. This project represents the first randomized controlled clinical trial in which is tested whether a non-commercial PGx test improves outcomes in a MDD naturalistic cohort. Moreover, the identification of new genetic variants associated with non-response or side effects will improve the efficacy of the test leading to a further cost-saving.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: March 1, 2023
• Est. primary completion date: September 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• A current diagnosis of unipolar depression according to Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)

• An Hamilton Depression Rating Scale (HAMD-17) score >=14

• Caucasian ethnicity.

Exclusion Criteria:

• Cognitive impairment (Mini Mental State Examination MMSE <24)

• Neurological disorders

• Diagnosis of MDD with psychotic features, bipolar I and II disorders, schizophrenia spectrum and other psychotic disorders, obsessive-compulsive disorder, post-traumatic stress disorder

• Substance abuse in the last 3 months

• Comorbidity with personality disorders (cluster A and/or B); pregnancy

• Comorbidity with other severe medical illness.

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Major Depressive Disorder

Intervention

Device:
• Pharmacogenomics test (PGx)
The clinicians of the TGTG group patients receive the PGx test report within 48 hours and all the participants start the new treatment within 72 hours. According with both Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) guidelines, the PGx report places the most ADs widespread in Italy, into three recommended categories: 1) "use as directed" (labelled as "Green"), 2) "use with caution" (labelled as "Yellow"), 3) "use with extreme caution" (labelled as "Red")

Locations

Country	Name	City	State
Italy	Department of Mental Health and Addiction	Brescia	BS

Sponsors (2)

Lead Sponsor	Collaborator
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia	IRCCS Istituto Centro San Giovanni di Dio- Fatebenefratelli

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Clinical response and remission self-reported	Changes in scores of depressive symptoms as measured by the Beck Depression Inventory II (BDI-II). Score on the BDI-II can range from 0 to 63 with higher scores indicating greater severity of depression	Baseline to 4 weeks, to 8 weeks and 12 weeks
Other	Psychosocial functioning	Changes in scores of psychosocial functioning as measured by the Mini-ICF-APP Social Functioning Scale (Mini-ICF-APP). All of items are rated using a 4-point scale, with higher ratings reflecting more severe limitations.	Baseline to 8 weeks and 12 weeks
Primary	Clinical response	Symptoms improvement as measured by the percent change in Hamilton Depression Rating Scale (HAMD-17). The higher the total score the more severe the depression	Baseline to 8 weeks
Secondary	Clinical response and remission	Response and remission rate at 4-, 8- and 12-weeks according to Hamilton Depression Rating Scale (HAMD-17). 0-7 not depressed; 8-13 mild; 14-18 moderate; 19-22 severe; >23 very severe	Baseline to 4 weeks, to 8 weeks and 12 weeks